about
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAsNano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoParadoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphomaThe genetic landscape of mutations in Burkitt lymphoma.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectActivity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsComparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculataRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaTumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialReduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.Genetic heterogeneity of diffuse large B-cell lymphomaGene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyYttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
P50
Q24618086-2625B1D4-9468-4FD9-9509-1C49469F57ABQ28488457-8F2333FC-07BE-4CA5-97D0-C47A85B8BC8DQ28535447-761C7149-F82E-4CE0-A01B-16EB20F2B3CCQ30453771-78705DAD-817D-4737-8B9F-F7BD873F1052Q30456436-51FFCB18-0AEB-48AB-B4A8-E6DAA1005C9AQ33342594-4774DF47-390F-4899-8629-B9F5D894A1B4Q33343445-BFD78D4F-52CA-496C-A601-CAFE08DE9540Q33347184-05D4B069-BC0D-42F9-8226-C5BC1C7CC624Q33363034-868B6223-BE53-433F-8A6E-763C63DF259EQ33377271-702BEEA8-E507-490C-A92B-0E75730AB237Q33377438-B6DD74DD-AAF3-4801-8829-D28FDC289674Q33383576-D1AA4C95-C123-4854-B0DF-1EF10A07C333Q33398415-E2F37F04-0741-4194-BC49-E42B4A33B208Q33402885-EC0387DC-6CFE-4C9A-B106-8B7EC75D5554Q33409608-47942FB5-DA82-4DA2-8630-1A552DA19BD9Q33411059-E3D41A13-F43D-4518-BFB6-62BF610D8E5BQ33642308-FDF3761B-9396-489B-BA65-7E41A9C31F33Q33710720-9E728F75-6A61-4A9B-8812-DAFF311DA57EQ34020461-D3A652D8-AE43-4FFC-9077-620198DDAB05Q34034389-D08ED051-378D-4EAB-AD23-613A802C8124Q34168689-59F2ED93-D113-4CDD-BDA3-32B5F3762273Q34645722-7629F3CB-6C88-47DE-8CAA-005DD369F761Q35002537-797B188A-3912-4CED-B698-31A00CA86408Q35140947-3DDE4698-4A4E-4E31-83BD-E5DED7DA1A6CQ36333526-03112FEB-8B33-451C-82F0-12565FF19AA9Q36481536-E29B440B-1DC4-4614-8CA2-8F62677982F3Q36567845-7827E449-B988-4CBB-AD49-EF8F55F83EE5Q36615084-074F1655-673D-46F0-B114-45C57E931BE4Q36814594-43216AE1-24F3-48AF-8AAD-D5604C4F4DBFQ36929714-7024E924-AF79-4D4F-AEA5-8F94929CA0E6Q37158257-63A4DB47-084F-47C5-A781-B9F38DA90A1EQ37158273-FE2F2FF9-7866-41B8-951E-0D10360265DAQ37390535-4466B7AD-9476-4C41-81AB-5DA72AADE85BQ37532169-BFCB02E1-7C7C-4E17-87EA-9DF36992CCD9Q37752447-3F33623F-26C8-42D4-9A04-1C1D9A4401CEQ37801865-91742DA2-98BA-426C-9A6B-575BF4F7DFB5Q39223255-8D14312F-F9DF-4BFA-B62E-A925F5EA98E2Q39335736-DD4D82DE-1466-4C9B-B0E3-0DC0FE74AB9BQ39392253-EDF00C87-C94E-4A74-964C-1C773862DF7BQ40235041-505DECA7-F0AF-475E-8B16-502652B3D5FE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Leo Gordon
@ast
Leo Gordon
@en
Leo Gordon
@es
Leo Gordon
@nl
Leo Gordon
@sl
type
label
Leo Gordon
@ast
Leo Gordon
@en
Leo Gordon
@es
Leo Gordon
@nl
Leo Gordon
@sl
prefLabel
Leo Gordon
@ast
Leo Gordon
@en
Leo Gordon
@es
Leo Gordon
@nl
Leo Gordon
@sl
P106
P1153
35426575800
P2038
Leo_Gordon2
P21
P31
P496
0000-0003-1666-7064